Format

Send to

Choose Destination
Trends Biotechnol. 2015 Aug;33(8):449-61. doi: 10.1016/j.tibtech.2015.05.001. Epub 2015 Jun 16.

Synthetic biology in cell-based cancer immunotherapy.

Author information

1
Department of Biomedical Engineering, Boston University, Boston, MA 02215, USA.
2
Department of Biomedical Engineering, Boston University, Boston, MA 02215, USA. Electronic address: wilwong@bu.edu.

Abstract

The adoptive transfer of genetically engineered T cells with cancer-targeting receptors has shown tremendous promise for eradicating tumors in clinical trials. This form of cellular immunotherapy presents a unique opportunity to incorporate advanced systems and synthetic biology approaches to create cancer therapeutics with novel functions. We first review the development of synthetic receptors, switches, and circuits to control the location, duration, and strength of T cell activity against tumors. In addition, we discuss the cellular engineering and genome editing of host cells (or the chassis) to improve the efficacy of cell-based cancer therapeutics, and to reduce the time and cost of manufacturing.

KEYWORDS:

cancer; chimeric antigen receptors; genetic circuits; immunotherapy; synthetic biology

PMID:
26088008
PMCID:
PMC4509852
DOI:
10.1016/j.tibtech.2015.05.001
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center